NasdaqGS:REGNBiotechs
Does Regeneron (REGN) Prioritizing In‑House R&D Over Deals Recast Its Long‑Term Risk‑Reward Profile?
Recently, Regeneron Pharmaceuticals’ leadership outlined a plan to prioritize internal research and development over large acquisitions as it approaches key patent expiries for flagship drugs Eylea and Dupixent, alongside continued progress in its partnered gene therapy programs with Intellia.
This renewed emphasis on in-house innovation, capital allocation discipline and lifecycle management for core franchises could materially influence how investors assess Regeneron’s longer-term growth...